Abstract | BACKGROUND: PROCEDURE: Patients enrolled on TXV (n = 498) and TXVI (n = 598) were assigned to low-risk (LR) or standard/high-risk (SHR) treatment arms (ClinicalTrials.gov identifiers: NCT00137111 and NCT00549848). Triglycerides were measured four times and were evaluable in 925 patients (TXV: n = 362; TXVI: n = 563). The genetic contribution was assessed using a triglyceride polygenic risk score ( triglyceride-PRS). Osteonecrosis, thrombosis, and pancreatitis were prospectively graded. RESULTS: CONCLUSION:
|
Authors | Emily R Finch, Colton A Smith, Wenjian Yang, Yiwei Liu, Nancy M Kornegay, John C Panetta, Kristine R Crews, Alejandro R Molinelli, Cheng Cheng, Deqing Pei, Laura B Ramsey, Seth E Karol, Hiroto Inaba, John T Sandlund, Monika Metzger, William E Evans, Sima Jeha, Ching-Hon Pui, Mary V Relling |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 67
Issue 1
Pg. e28040
(01 2020)
ISSN: 1545-5017 [Electronic] United States |
PMID | 31612640
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2019 Wiley Periodicals, Inc. |
Chemical References |
|
Topics |
- Adolescent
- Asparaginase
(adverse effects, chemistry)
- Child
- Child, Preschool
- Drug Compounding
- Female
- Follow-Up Studies
- Humans
- Hypertriglyceridemia
(chemically induced, pathology)
- Infant
- Male
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy, pathology)
- Prognosis
|